Enzolytics Inc (ENZC)

[MAGA_PATRIOT]

Thanks thenextbigstock.... All of my shares are long. I've been holding since March 2020.

Also, just a reminder that everything I've been posting is my own interpretation of the most orchestrated & controlled pattern that I've ever experienced. Ive just been trying to show how controlled/orchestrated/predictable it really is, and that the 9 month destruction/fakedown of our pps has nothing to do with the company itself, nor do we (retail) have anything to do with it. Whether or not my interpretations are correct, are still to be determined, but I refuse to buy into the notion that we closed at .1162 on 1.1.2021, but somehow we now sit in the .10s.

In other words, Since 1.12.2021 when we closed at .1162, all of the following has happened, yet we are worth less? LOL... (Thanks to Mutat for posting the Timeline Link to all items below)

And lets not forget that what is not shown below is the C3 projection of $100B in earnings over the first 10 years; but we're supposed to believe that with each met milestone, each successful test, each partner/collaborator, etc...., we are worth less.... LOL... Not buying it!

1.19.2021 - Official Filing Receipt for the MS Patent Application

2.1.2021 - Discovery of 7 Newly Identified Conserved Target Sites of the HIV Virus

2.9.2021 - Study of the Antiviral Effect of IPF on the replication of human coronavirus strain 229E (HCoV-229E)

2.16.2021 - Announced In-Vitro Test Results for ITV-1 Against HCoV-229E

2.22.2021 - Discovery of 11 Newly Identified Conserved Target Sites of the SARS-CoV-2

2.22.2021 - Formation of International Medical Partners (IMBL), a Bulgarian LLC

3.8.2021 - Discovery & Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus

3.16.2021 - Distribution and Operational Agreement for ITV-1 with IMBL

3.18.2021 - Filing of Provisional Patent for Monoclonal Antibodies

3.22.2021 - Filing of Updated NIH Grant Application to Include Newly ID’d Conserved Sites

4.5.2021 - Coronavirus Targeted Epitopes Claimed in Pending Patents are Verified as Fully Conserved

4.14.2021 - Presentation of Technology on the Emerging Growth Conference

4.19.2021 - Updates on Multiple Therapeutics’ Platforms and Initiatives

5.11.2021 - Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm

5.12.2021 - Granted a Distributorship License to Rosetta Lifecare Bulgaria to Distribute ITV-1 in Designated Areas

5.17.2021 - Enzolytics & Intel Co-Author White Paper on use of AI

5.26.2021 - Announced the Discovery of Conserved, Immutable Sites on HTLV-1 & Plans to Produce mAbs Targeting Sites

6.7.2021 - Updates on Therapeutic Protocol to Produce mAbs to Address Ongoing & Future Pandemics

6.14.2021 - Updates on Completion of Clinical Trials for ITV-1 & Plans for Distribution throughout Europe

6.20.2021 - Announced the Signing of LOI w/ Creative Biolabs, Inc. for Licensing & Commercialization of anti-HTLV-1 mAbs

6.22.2021 - Site Visit of VetProm Facilities for Production of ITV-1 for Clinical Studies

7.26.2021 - Appointment of Steve Sharabura as President of RobustoMed

7.27.2021 - COO, Dr. Gaurav Chandra Featured on C&EN Discovery Report

7.29.2021 - Agreements with Danhson and Clinic Design to Advance ITV-1 to Production & Clinical Trials

8.25.2021 - Updates on the Production of Anti-Coronavirus mAbs & the Production / Clinical Trials of ITV-1

8.30.2021 - Study of the Antiviral Effect of IPF on the Replication of Human Herpes Simplex Virus

9.18.2021 - Updates on Two Therapy Platforms for Treating HIV

10.7.2021 - Enzolytics Inc. and Samsung Biologics Announce CDMO for Anti-HIV and Anti-SARS-CoV-2 mAbs

10.13.2021 - Study of the Cytotoxic Effect of IPF on Cell Cultures

11.8.2021 - Announced Program for Creation of Animal mAbs Using Hybridoma & Phage Display Tech

11.12.2021 - RobustoMed Received Initial Funding to Market Products in Central & Latin America

11.17.2021 - Announced Production & Sale in North America of Enzolytics IPF Immune

11.19.2021 - Topographic Study of Cells Infected w/ HCoV-229E/HSV-1 & Treated w/ IPF

12.1.2021 - Yuan Article “Demystifying the Human Microbiome Using AI” by COO, Dr. Gaurav Chandra

12.2.2021 - Enzolytics Announces Progress As It Recognizes World AIDS Day

$ENZC